Gain Therapeutics reports a $3.16 million net loss in the third quarter
Key Facts
Gain Therapeutics reported a net loss of $3,160,408 in the third quarter of 2026, or $0.07 per share, according to results announced by the company. The loss was $5,284,373, or $0.15 per share, in the same quarter of 2025. The comparison reflects a year-on-year narrowing of the net loss, while the stock remained lower at $1.09 at the close of the Nov. 9 session, according to EL7 data. The company said research and development expenses were among the main items to decline during the quarter. The available information did not include analyst estimates for comparison with the result.
Research and development expenses were about $1.4 million in the third quarter, compared with $2.8 million in the year-earlier period. The company said the $1.4 million decline was primarily related to lower costs for the rexaceract program, optimization of its program portfolio and lower personnel expenses. General and administrative expenses also fell to $1.8 million from $1.9 million. The company attributed the $0.1 million decline primarily to lower professional fees and personnel expenses. These items show that the reduction in expenses covered research and development and administration, with research and development spending remaining higher than general and administrative expenses during the period.
Cash and cash equivalents totaled $11.7 million on September 30, 2026, compared with $20.8 million on December 31, 2025, according to the company’s statement. In an update on rexaceract, Gain Therapeutics said 12 participants had completed 12 months of treatment by August 31, 2026. It added that the participants’ movement scores remained stable compared with baseline and that they showed no progression in motor symptoms of Parkinson’s disease after 12 months of dosing. Chief Executive Gene Mack said participants showed no progression in motor symptoms after that period. These results remain part of the study follow-up described by the company and do not represent an announcement of a Phase 2 trial result.
The company said it had observed no new safety signals in the long-term follow-up data. It also said the rate of treatment-emergent adverse events was lower during the nine-month open-label extension period than during the initial three-month dosing period. In an August 11 update, the company had said that the start of a Phase 2 trial of rexaceract in people with Parkinson’s disease was expected in the third quarter of 2026; that update did not include a later result on whether the trial had begun. In the near term, Gain Therapeutics announced scientific poster presentations at two conferences in November: the IAPRD conference in Milan from November 11 to 14, and the Neuroscience meeting in Washington from November 14 to 18. The company scheduled a rexaceract data poster presentation in a guided poster tour on November 13 between 3:30 and 4:30 p.m. Central European Time, while it expects to select the initial indication for clinical development of candidate GT-04686 in the fourth quarter of 2026.